the fy21 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy21 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy21 pcrp overarching challenges:

• improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

• the mental and emotional health of patients and their families/caregivers
• impact of quality of life considerations on decision-making after diagnosis and/or treatment
• identification of vulnerable groups of men and their families at great risk of quality of life detriments
• translation of factors or interventions that improve quality of life outcomes and overall health and wellness
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions

(https://www.ncc n.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• define the biology of lethal prostate cancer to reduce death

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

https://cdmrp.army.mil/funding/pcrp

early investigator research award – letter of intent due june 17, 2021

by march 31, 2022

postdoctoral principal investigators (pis):

• must possess a doctoral degree (or equivalent)
• have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)
• supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
• pis must have a designated mentor who is an experienced prostate cancer researcher.
• must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.

must address at least one of the fy21 pcrp overarching challenges.

• the maximum allowable funding for the entire period of performance is $300,000 for direct costs.
• the maximum period of performance is 2 years.

physician research award – letter of intent due june 17, 2021

at the time of application submission, the pi must be either:

• in the last year of an accredited medical residency or medical fellowship program

or

within 5 years of having initiated a faculty appointment (including instructor positions)

• supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• pis must have a designated mentor with an established research program in prostate cancer.
• applications are strongly encouraged to demonstrate protection of at least 40% of the pi’s time for prostate cancer research (not required to be exclusive to this award). 
• must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• must address at least one of the fy21 pcrp overarching challenges.
• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• the maximum period of performance is 4 years

the harrington scholar-innovator award recognizes physician-scientist innovators throughout the us and canada, whose research has the potential to change standard of care. the scholar-innovator award provides research and drug development support to help bridge the gap between basic discovery and the clinical realm.

up to twelve harrington scholar-innovator awards are made each year through a competitive selection process.

together with the quebec consortium for drug discovery (cqdm), brain canada is pleased to share an upcoming funding opportunity for canadian researchers. cqdm’s quantum leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.

projects selected as part of the quantum leap program focus on developing cutting-edge technologies with the potential to significantly advance the r&d activities of cqdm’s pharmaceutical members. quantum leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

brain canada is partnering with the quantum leap pharma-led funding program for drug discovery research on eligible brain related projects.

please note: budget structures can vary depending on each project, please contact cqdm to confirm eligibility before applying,

the cmhc award for northern or remote research is a bursary of up to $5,000.

it allows people doing housing research or fieldwork to undertake engagement and consultations activities (including travel) in northern or remote areas of canada. the field of research must be in one of the national housing strategy’s priority areas.

the goal is to build knowledge and fill research gaps on northern or remote housing.

if this award is of interest, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca for more information.

the fy21 defense appropriations act provides funding to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 scirp program announcements and general application instructions for the following award mechanisms will be posted on the grants.gov website. 

applications submitted to the fy21 scirp must address one or more of the following focus areas*:

• psychosocial issues relevant to people with sci, their families, and/or their care-partners
• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of  treatment efficacies
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 24, 2021

principal investigator (pi): investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early- career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund phase 0, 1, or 2 clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (sci) and its consequences.
• alternative study designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial.
• applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is  $3 million (m) for direct costs.
• the maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions e available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil/scirp).

*detailed fy21 scirp focus areas

applications submitted to the fy21 scirp must address one or more of the following focus areas:

• *updated fy21* psychosocial issues relevant to people with sci, their families, and/or their care-partners:

o   applications should directly address, or show clear relevance to, the needs of service members and veterans.

o   projects should provide an understanding of critical factors promoting psychosocial wellbeing, leading to implementation of potential treatments and interventions.

o   studies addressing social isolation, loneliness, depression as well as resilience, self-efficacy, and interactions between people living with sci and their care-partners are especially encouraged. 

o   preclinical animal studies are not responsive to this focus area.

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes:

o   responsive projects may include surgical and acute care management of sci.

o   therapeutics (devices and pharmacologic interventions) to stabilize sci in the pre-hospital environment and during transport are encouraged.

o   applications proposing neuroprotective interventions need to demonstrate a clinically feasible window for treatment and more than an incremental improvement over existing therapies.

• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies:

o   biomarkers must focus on diagnosis, prognosis, progression, and/or recovery of sci.

o   projects with a clear link between a biomarker and underlying physiology are encouraged.  projects can include imaging and other modalities.

o   applications should demonstrate a clear path to clinical use.

o   biomarker studies directed at identifying the best single or combination of treatments for individuals (personalized medicine) are encouraged.

• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain:

o   studies of the mechanisms of dysfunction and neuropathic pain specific to sci must demonstrate a clear path from increased understanding to advancing treatments.

o   studies addressing the needs of and treatments for individuals with sci across the full lifespan from acute to chronic injury are encouraged.

• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci:

o   studies that address critical questions of dosing, targeting, or safety required to move the research toward clinical use are supported.

o   applications studying mechanisms of regeneration or identifying novel therapeutic targets must include a feasible projected pathway for translation and clinical implementation.

o   basic research projects designed to understand general mechanisms underlying axonal sprouting, regeneration, or neuroplasticity are discouraged unless they directly address translatable approaches.

point of contact:

cdmrp help desk

301-682-5507

usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

¹ funding is provided through the fy21 appropriation for peer-reviewed spinal cord research

the fy21 defense appropriations act provides funding to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 scirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy21 scirp must address one or more of the following focus areas*:

• psychosocial issues relevant to people with sci, their families, and/or their care-partners
• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of  treatment efficacies
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 24, 2021

principal investigator (pi): investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
  • fund phase 0, 1, or 2 clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (sci) and its consequences.
  • alternative study designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial.
  • applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $3 million (m) for direct costs.
• the maximum period of performance is 4 years.

translational research award – preproposal due may 24, 2021

principal investigator: investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund studies that accelerate the movement of promising ideas in sci research into clinical applications.
• applications must include at least one individual with lived sci experience as a member of the research team.
• preliminary data required.
• the scirp translational research award may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $1.25 m for direct costs.
• the maximum period of performance is 3 years.

investigator-initiated research award – preproposal due may 24, 2021

principal investigator: investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund sci-related research that has the potential to make an important contribution to sci research, patient care, and/or quality of life.
• studies focused exclusively on target identification are discouraged.
• preliminary data required.
• clinical trials are not allowed.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions are available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil/scirp).

*detailed fy21 scirp focus areas

applications submitted to the fy21 scirp must address one or more of the following focus areas:

• *updated fy21* psychosocial issues relevant to people with sci, their families, and/or their care-partners:

o    applications should directly address, or show clear relevance to, the needs of service members and veterans.

o    projects should provide an understanding of critical factors promoting psychosocial wellbeing, leading to implementation of potential treatments and interventions.

o    studies addressing social isolation, loneliness, depression as well as resilience, self-efficacy, and interactions between people living with sci and their care-partners are especially encouraged. 

o    preclinical animal studies are not responsive to this focus area.

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes:

o    responsive projects may include surgical and acute care management of sci.

o    therapeutics (devices and pharmacologic interventions) to stabilize sci in the pre-hospital environment and during transport are encouraged.

o    applications proposing neuroprotective interventions need to demonstrate a clinically feasible window for treatment and more than an incremental improvement over existing therapies.

• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies:

o    biomarkers must focus on diagnosis, prognosis, progression, and/or recovery of sci.

o    projects with a clear link between a biomarker and underlying physiology are encouraged.  projects can include imaging and other modalities.

o    applications should demonstrate a clear path to clinical use.

o    biomarker studies directed at identifying the best single or combination of treatments for individuals (personalized medicine) are encouraged.

• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain:

o    studies of the mechanisms of dysfunction and neuropathic pain specific to sci must demonstrate a clear path from increased understanding to advancing treatments.

o    studies addressing the needs of and treatments for individuals with sci across the full lifespan from acute to chronic injury are encouraged.

• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci:

o    studies that address critical questions of dosing, targeting, or safety required to move the research toward clinical use are supported.

o    applications studying mechanisms of regeneration or identifying novel therapeutic targets must include a feasible projected pathway for translation and clinical implementation.

o    basic research projects designed to understand general mechanisms underlying axonal sprouting, regeneration, or neuroplasticity are discouraged unless they directly address translatable approaches.

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

¹ funding is provided through the fy21 appropriation for peer-reviewed spinal cord research

behavioral health science award  - letter of intent due july 29, 2021

independent investigator with a faculty-level appointment (or equivalent).

• letter of intent is required. an invitation to submit a full application is not required.
• supports research that span the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data required.
• pilot clinical trials are allowed.
• the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 4 years.

career development award – fellow option – letter of intent due july 29, 2021

principal investigator (pi): independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research

• letter of intent is required. an invitation to submit a full application is not required.
• supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of performance is $400,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

translational team science award – letter of intent due july 29, 2021

at least two, and a maximum of three, pis must partner in one overarching correlative or translational research study.

• letter of intent is required.  an invitation to submit a full application is not required.
• emphasizes multi-pi, multidisciplinary collaborations.
• supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research.
• not intended to support high throughput screenings, sequencing, etc.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
  • the maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 4 years.
  • at least one of the pis is encouraged to be a military or us department of veterans affairs investigator.

idea award – preproposal due may 20, 2021

independent investigator with a faculty-level appointment (or equivalent).

• preproposal is required; application submission is by invitation only.
• supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research.
• emphasis on innovation.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years

impact award – preproposal due may 20, 2021

independent investigators at or above the level of assistant professor (or equivalent) are eligible to submit an application.

• preproposal is required; application submission is by invitation only.
• supports hypothesis-driven, high impact research.
• encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues which, if successfully addressed, have the potential to make a near term, major impact on one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
• the maximum allowable funding for the entire period of performance is $1,250,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

fy21 ocrp program announcements and general application instructions for the following award mechanism are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/ocrp

omics consortium award – preapplication due june 24, 2021

must be an independent investigator at or above the level of assistant professor (or equivalent).

• supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer, with an emphasis on early detection and screening.

two options are available:

omics development award option:

• funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
• ovarian cancer advocate(s) are required on the research team.
• funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in fy23, pending availability of funds.

omics consortium award option:

• the research effort will provide immediate benefits for ovarian cancer patients in initial diagnosis and therapy and the end result will lead to improvements in early detection and screening detection of ovarian cancer. 
• consortium should maximize the use of resources and minimize unnecessary duplication among consortium members by sharing resources among all consortium members.
• ovarian cancer advocate(s) are required on the research team.
• submission of a letter of intent is required prior to full application submission.

omics development award option:

• maximum funding of $400,000 for direct costs (plus indirect costs).
• maximum period of performance is 2 years.

omics consortium award option:

• maximum funding of $2.5 million for direct costs (plus indirect costs) from fy21 and future appropriations.
• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

connection grants are expected to respond to the objectives of the connection program.

these grants support events and outreach activities geared toward short-term, targeted knowledge mobilization initiatives. these events and activities represent opportunities to exchange knowledge and to engage with participants on research issues of value to them. events and outreach activities funded by a connection grant can often serve as a first step toward more comprehensive and longer-term projects.

connection grants support workshops, colloquiums, conferences, forums, summer institutes, or other events or outreach activities that facilitate:

• disciplinary and/or interdisciplinary exchanges in the social sciences and humanities;
• scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
• intersectoral exchanges between academic researchers in the social sciences and humanities and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
• international research collaboration and scholarly exchanges with researchers, 世界杯2022赛程表淘汰赛 and non-academic partners from other countries.